Par Pharmaceutical Companies Expenses: 193.43M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PRX Expenses Rankings
| Overall | 61st percentile | 1739 of 4491 |
| Sector | 77th percentile | 109 of 477 in Healthcare |
| Industry | 72nd percentile | 3 of 11 in Drugs - Generic |
PRX Expenses Range, Past 5 Years
| Minimum | 2.56M | Dec 1993 |
| Maximum | 202.44M | Jun 2006 |
| Average | 57.51M |
About Expenses
Any cost incurred by a business for revenue generating activities.
YCharts calculates this number as Total Revenues - Net Income.
Learn More
You may also be interested in these PRX related companies
PRX News
Robbins Umeda LLP Announces an Investigation of Par Pharmaceutical Companies, Inc.
Feb 06, 12:01PM Business Wire
Feb 06, 12:01PM Business Wire
$PRX New 52 Week High - Crossed daily highs resistance. Next resistance 39.00 from 1/4/2011.
about 9 days ago by TradeIdeasQuant
about 9 days ago by TradeIdeasQuant
Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2011 Results on February 28, 2012
Jan 31, 9:00AM PR Newswire
Jan 31, 9:00AM PR Newswire
I don't think the pricing fixing case against $PRX is going to have much of an effect. Last I checked they have about 50 other products..
about 29 days ago by bradloncar
about 29 days ago by bradloncar
UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Shaping Up To Be Strong Growth Story
Jan 09, 10:51AM Street Insider
Jan 09, 10:51AM Street Insider
Needham & Company: Thoughts Heading Into Par Pharmaceutical's (PRX) January 6, Analyst Day; Generics Take Center Stage
Jan 06, 11:20AM Street Insider
Jan 06, 11:20AM Street Insider
Listen to $PRX Par Pharmaceutical Companies Investor Day - live at 09:00 AM, ondemand after - http://stks.co/1nwc
about 37 days ago by earningscast
about 37 days ago by earningscast
Leerink Swann Remains Positive on Shares of Par Pharmaceutical (PRX) Following Meeting With Management
Nov 30, 10:59AM Street Insider
Nov 30, 10:59AM Street Insider
Par Pharma promotes Thomas Haughey to President and Paul Campanell as COO
Nov 22, 8:36AM FlyOnTheWall
Nov 22, 8:36AM FlyOnTheWall
Magic Formula Links for 8/24/2011 $AMAT $GTAT $MHP $PRX $GME http://stks.co/1Bx
about 171 days ago by MagicDiligence
about 171 days ago by MagicDiligence
Intellipharmaceutics and Par Expand Development and Commercialization Agreement $IPCI $PRX http://stks.co/PK
about 178 days ago by IPCI
about 178 days ago by IPCI
$PRX http://chart.ly/jeylvad it was the gap up and close back over the 20-day MA so maybe over $25 or $25.40 on good volume
about 261 days ago by StockTiger
about 261 days ago by StockTiger
Par Pharma - Buried in the Generic Drugs Battlefield $PRX $TEVA $WPI $MYL $NVS http://stk.ly/kB9i9C
about 276 days ago by MagicDiligence
about 276 days ago by MagicDiligence
$PRX $34.97 HAUGHEY THOMAS officer (EVP, CAO, General Counsel) S 198,860 @ $34.76 amnt $6,913,347 proc'd ($40,803) 5/10/2011
about 276 days ago by canarionyc
about 276 days ago by canarionyc
$PRX http://chart.ly/wp6ct45 from watch list - not a big move from today's trigger but volume good at 167% of ave full day
about 279 days ago by StockTiger
about 279 days ago by StockTiger
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PRX | 36.55 | -0.50 | -1.35% | 1.33B |
| HNP | 25.02 | 0.03 | 0.12% | 7.54B |
| GRA | 54.83 | -0.27 | -0.49% | 4.05B |
| WFC | 30.26 | -0.32 | -1.05% | 159.58B |
| TRN | 33.14 | -0.45 | -1.34% | 2.66B |
| SWM | 70.32 | -1.18 | -1.65% | 1.13B |
| DUK | 21.48 | 0.02 | 0.09% | 28.60B |
| HUN | 13.38 | -0.02 | -0.15% | 3.24B |
| CMG | 376.45 | -0.04 | -0.01% | 11.78B |
| CAT | 111.75 | -1.08 | -0.96% | 72.26B |
